Search results for "Ischaemic stroke"

showing 10 items of 25 documents

Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension

2019

Uric acid (UA) is a promising protective treatment in ischaemic stroke, but the precise molecular targets underlying its in vivo beneficial actions remain unclear. High concentrations of UA inhibit angiogenesis of cultured endothelial cells via Krüppel-like factor 2 (KLF)-induced downregulation of vascular endothelial growth factor (VEGF), a pro-angiogenic mediator that is able to increase blood–brain barrier (BBB) permeability in acute stroke. Here, we investigated whether UA treatment after ischaemic stroke protects brain endothelial cell functions and modulates the KLF2-VEGF-A axis. Transient intraluminal middle cerebral artery (MCA) occlusion/reperfusion was induced in adult male sponta…

0301 basic medicineMaleVascular Endothelial Growth Factor AVascular endothelial growth factor-AAngiogenesisBiochemistryRats Inbred WKYAntioxidantschemistry.chemical_compound0302 clinical medicineRats Inbred SHRIschaemic strokeEvans BlueBlood-brain barrierBrainKrüppel-like factor 2Vascular endothelial growth factorEndothelial stem cellStrokeVascular endothelial growth factor Amedicine.anatomical_structureNeuroprotective AgentsTreatment OutcomeBlood-Brain Barrier030220 oncology & carcinogenesisHypertensioncardiovascular systemmedicine.symptommedicine.medical_specialtyKruppel-Like Transcription FactorsBrain damageBlood–brain barrierNeuroprotectionCell Line03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineAnimalsHumanscardiovascular diseasesPharmacologybusiness.industryRatsUric Acid030104 developmental biologyEndocrinologychemistryEndothelium VascularAngiogenesisbusinessBiomarkers
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

TC perfusionale nell'ischemia cerebrale acuta: Valore predittivo dei parametri di perfusione cerebrale nel discriminare il tessuto vitale da quello i…

2007

Purpose. The aim of this study was to assess the value of computed tomography (CT) perfusion parameters in differentiating tissue viability in acute stoke patients. Materials and methods. Thirteen patients (mean age 63.3 years) with nonhaemorrhagic stroke underwent multidetector perfusion CT within 3 h of symptom onset. Images were continuously acquired at the basal ganglia over 40 s during injection of 90 ml of iodinated contrast medium injected at a rate of 9 ml/s with a 9-s delay. Z-axis coverage was 20 mm. All patients underwent diffusion-weighted magnetic resonance imaging (DWI) within 12 h of perfusion CT to define the extent of the infarct. Perfusion CT data were analysed in regions …

AdultMaleRadiology Nuclear Medicine and ImagingTime FactorContrast MediaPredictive Value of TestSensitivity and SpecificityBasal GangliaBrain IschemiaImage Processing Computer-AssistedIschaemic strokeAgedAged 80 and overTissue SurvivalPerfusion CTBlood VolumeBrainCerebral InfarctionMiddle AgedPerfusionRadiographic Image EnhancementStrokeDiffusion Magnetic Resonance ImagingROC CurveCerebrovascular CirculationFemaleTomography X-Ray ComputedCTHuman
researchProduct

Domain-specific trends in cognitive impairment after acute ischaemic stroke.

2012

Little is known about the pattern of subacute cognitive domain impairments after ischaemic stroke, nor the temporal evolution of such impairments. Our objective was to investigate the pattern of cognitive impairment in different neuropsychological domains up to a year after ischaemic stroke. We included prospectively collected data from an observational database of stroke patients at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. Patients were categorised into temporal groups according to the time between the index stroke and neuropsychological profiling. The prevalence of impairment in different cognitive domains was then compared between these categories. …

AdultMalemedicine.medical_specialtyNeurologyTime Factorsmedicine.medical_treatmentNeuropsychological TestsStatistics NonparametricCohort StudiesPhysical medicine and rehabilitationmedicineDementiaHumansNeuroradiologyAgedAged 80 and overischaemic strokeRehabilitationSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryNeuropsychologyCognitionMiddle Agedmedicine.diseaseStrokeNeurologyCohortPhysical therapyFemaleNeurology (clinical)Verbal memorybusinessCognition DisordersJournal of neurology
researchProduct

The PFO anatomy evaluation as possible tool to stratify the associated risks and the benefits arising from the closure

2010

Aims According to the current guidelines, the patent foramen ovale (PFO) is still considered a qualitative factor and, as a consequence, its closure is recommended just on the basis of its ‘presence’. Methods and results In the year 2008, we evaluated 25 patients (mean age 62.7) with acute cerebrovascular event and 92 patients (mean age 27.3) suffering from migraine with aura. No PFO was reported in 79 patients. A venous-to-arterial circulation shunt had been shown in 38 patients (29 subjects with migraine and 9 subjects with prior stroke). According to the number of microbubbles arrived during the Valsava manoeuvre, we found: 25 small PFO, 6 moderate PFO, and 6 severe PFO. In the baseline …

AdultMalemedicine.medical_specialtyValsalva ManeuverMigraine with AuraPopulationForamen Ovale PatentRisk AssessmentBrain IschemiaRisk FactorsIschaemic strokeConfidence IntervalsOdds RatiomedicineForamenHumansRadiology Nuclear Medicine and imagingeducationeducation.field_of_studybusiness.industryMean ageGeneral MedicineMiddle AgedPrognosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMigraine with auraSurgeryItalyMigraineEchocardiographyCase-Control StudiesMultivariate AnalysisIschemic strokePatent foramen ovaleFemalePFOevaluationmedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.

2021

International audience; Background and purpose The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial. Methods This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists. Results Of 473 patients randomi…

Adultmedicine.medical_specialtyStroke patientAuraSeptal Occluder Device[SDV]Life Sciences [q-bio]Migraine DisordersForamen Ovale PatentBrain Ischemia03 medical and health sciences0302 clinical medicineInternal medicineIschaemic strokemedicineHumans030212 general & internal medicineClosure (psychology)Foramen ovale (heart)business.industryMiddle Agedmedicine.diseaseClinical trialStrokemedicine.anatomical_structureTreatment OutcomeNeurologyMigraineCardiologyPatent foramen ovaleFemaleNeurology (clinical)business030217 neurology & neurosurgeryPlatelet Aggregation InhibitorsEuropean journal of neurologyREFERENCES
researchProduct

Diagnostic Procedures in Ischaemic Stroke Patients with Dementia. A Population-Based Study

2012

Background Dementia is a frequent condition in stroke patients. Aims To investigate the effect of dementia on access to diagnostic procedures in ischaemic stroke patients. Methods All cases of ischaemic stroke from 2006 to 2010 were identified from the population-based Stroke Registry of Dijon, France. Patients' characteristics were recorded, as was the use of brain computed tomography scans, brain magnetic resonance imaging, electrocardiogram, echocardiography, and Doppler ultrasonography of the cervical arteries. Dementia was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders-IV criteria. Logistic regression models were used to evaluate the associations between d…

Aged 80 and overMalemedicine.medical_specialtybusiness.industryMiddle AgedStroke caremedicine.diseaseStrokePopulation based studyNeurologyEmergency medicineEpidemiologyIschaemic strokePhysical therapyHumansMedicineDementiaDementiaFemalebusinessStrokeAgedInternational Journal of Stroke
researchProduct

Serum pentraxin 3 as a clinical biomarker of branch atheromatous disease: a marker of brain ischaemia or an atherotrombosis marker?

2020

Atheromatous diseasePathologymedicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryBiomarkerBrain IschemiaClinical biomarkerSerum Amyloid P-ComponentC-Reactive ProteinNeurologyIschaemic strokemedicineHumansNeurology (clinical)businessBiomarkersHumanPentraxin-3European journal of neurologyReferences
researchProduct

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strat…

2021

Abstract Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiova…

CHOLESTERYL ESTER TRANSFERTO-MODERATE HYPERTRIGLYCERIDEMIALipoprotein remnants030204 cardiovascular system & hematologyBioinformaticsResidual riskBrain Ischemiachemistry.chemical_compoundVoeding Metabolisme en Genomica0302 clinical medicineIschaemic strokeAcademicSubjects/MED00200Myocardial infarctionLOW-GRADE INFLAMMATIONALL-CAUSE MORTALITY[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism0303 health sciencesAtherosclerotic cardiovascular diseasedigestive oral and skin physiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseMetabolism and Genomics3. Good healthStrokeLOW-DENSITY LIPOPROTEINSCardiovascular DiseasesMetabolisme en GenomicaCORONARY-ARTERY-DISEASENutrition Metabolism and GenomicsCardiology and Cardiovascular MedicineB-CONTAINING LIPOPROTEINSLipoproteinsTriglyceride-rich lipoproteinsHEART-DISEASE03 medical and health sciencesSpecial ArticleVoedingmedicineHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIATriglycerides030304 developmental biologyNutritionVLAGTriglyceridebusiness.industryAPO-Bmedicine.diseaseAtherosclerosisResidual riskIncreased riskchemistry3121 General medicine internal medicine and other clinical medicineEuropean atherosclerosis societybusinessLipoprotein
researchProduct

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy

2019

AbstractThe most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60%…

Carotid Artery DiseasesMaleRisk0301 basic medicinemedicine.medical_specialtyCardiologyHemorrhageThromboembolic stroke030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineRivaroxabanCarotid artery diseaseInternal medicineIschaemic strokeMyocardial RevascularizationmedicineHumansAgedAspirinbusiness.industryIncidence (epidemiology)Atherosclerotic diseaseAnticoagulantsAtrial fibrillationHematologyMiddle AgedAtherosclerosismedicine.diseaseClopidogrelReview articleCarotid Arteries030104 developmental biology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCardiovascular Diseasesanti-platelet; anti-thrombotic therapy; anticoagulant; aspirin; carotid artery disease; rivaroxabanCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessPlatelet Aggregation InhibitorsThrombosis and Haemostasis
researchProduct